about
Characterization of Pulmonary Vein Dimensions Using High-Definition 64-Slice Computed Tomography prior to Radiofrequency Catheter Ablation for Atrial Fibrillation.Congenital coronary anomalies detected by coronary computed tomography compared to invasive coronary angiography.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Age-related normal structural and functional ventricular values in cardiac function assessed by magnetic resonanceCoronary dominance and prognosis in patients undergoing coronary computed tomographic angiography: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registryCalcification Characteristics of Low-Flow Low-Gradient Severe Aortic Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement.Coronary Wall Structural Changes in Patients With Kawasaki Disease: New Insights From Optical Coherence Tomography (OCT).Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.Coronary dominance and prognosis in patients with chronic total occlusion treated with percutaneous coronary intervention.Comparison of Outcomes in Men Versus Women After Percutaneous Coronary Intervention for Chronic Total Occlusion.Impact of age and sex on left ventricular function determined by coronary computed tomographic angiography: results from the prospective multicentre CONFIRM study.Survival after percutaneous coronary intervention for chronic total occlusion in elderly patients.Long-Term Follow-Up of Patients With Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion.Impact of body mass index on long-term mortality in women and men undergoing percutaneous coronary intervention for chronic total occlusion.Left ventricular non-compaction: prevalence in congenital heart disease.Survival after percutaneous coronary intervention for chronic total occlusion.Complete graft dehiscence 8 months after repair of acute type A aortic dissectionMyocardial perfusion imaging with 13N-ammonia PET is a strong predictor for outcome.Early and late mortality in patients undergoing transcatheter aortic valve implantation: comparison of the novel EuroScore II with established risk scores.Regurgitation after Edwards SAPIEN valve implantation: truly paravalvular or 'supra-skirtal'?Registry for the Evaluation of the PROgnostic value of a novel integrated imaging approach combining Single Photon Emission Computed Tomography with coronary calcification imaging (REPROSPECT).Coronary artery stents: influence of adaptive statistical iterative reconstruction on image quality using 64-HDCT.Impact of fibrosis and sympathetic activity on coronary flow reserve in hypertrophiccardiomyopathy.Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease.Successful Repair of a Bicuspid Pulmonary Autograft Valve Causing Early Insufficiency After a Ross Procedure.Temporal changes in outcomes of women and men undergoing percutaneous coronary intervention for chronic total occlusion: 2005-2013.Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function.Impact of anemia on long-term outcomes after percutaneous coronary intervention for chronic total occlusion.N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.Cadmium-zinc-telluride myocardial perfusion imaging in obese patients.Clinical Implications of Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion: Role of Antegrade and Retrograde Crossing Techniques.Preprocedural Leucocyte Count Predicts Risk in Patients with Coronary Chronic Total Occlusion.Comparison of Benefit of Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients With Versus Without Reduced (≤40%) Left Ventricular Ejection Fraction.Transcatheter aortic valve-in-valve implantation: clinical outcome as defined by VARC-2 and postprocedural valve dysfunction according to the primary mode of bioprosthesis failure.Caffeic acid phenethyl ester inhibits endothelial tissue factor expression.Development of a new bioactivatable fluorescent probe for quantification of apolipoprotein A-I proteolytic degradation in vitro and in vivo.CT coronary angiography: impact of adapted statistical iterative reconstruction (ASIR) on coronary stenosis and plaque composition analysis.Reduced left ventricular compacta thickness: a novel echocardiographic criterion for non-compaction cardiomyopathy.
P50
Q33895162-6D3AC9B6-FDB7-417E-BDF3-EE5BF1B804FEQ33987834-5E5E73BD-0367-4231-8E30-6EAAF6136386Q34257466-1388AD25-50C2-4C49-87CF-D3A57FB00EFDQ34580345-A54F3764-F95C-4DAD-AAB2-6AD90761D720Q35861587-9ECCE6D8-D354-4569-927B-E3D2C4B4180AQ36075723-51321E76-3EBD-4EEE-ACA7-ABBC5E97A460Q36141438-5E625495-274C-41E3-89FE-D203C50A9A86Q36242530-7D01A663-4A39-46A2-8A00-36E03331883EQ38384596-D8E04FCD-1029-4C4C-90DE-3949C01DD03AQ38511039-F2CB48C1-4FD6-4708-81B2-366694DE9FA8Q38631031-86A8B43C-D496-403A-A556-01814625E63BQ38824353-BC01940D-98F7-462D-88BF-8AF24C527462Q38837554-3C92F207-2D78-4B29-868A-65C8BF62FF53Q39170460-CFA46274-8A9C-4433-AA3B-67BD4A7F28D2Q39332872-5FAEB5E1-3C2E-4A2C-B421-111709DEE25DQ39353998-C02DD880-3CA3-4D9E-897D-224F5373BF40Q39601632-998DEE71-6259-4555-95FA-AF438AECEDF1Q39718315-A7FFDCD4-FA25-4BAB-BD1A-EFD4248C538FQ41816988-B0107A6B-30E5-4642-A02C-79F1FDA95375Q43759669-65CAE954-5580-4F6D-8309-0E9D4954A491Q43778018-E6B4E146-EA4C-4712-8A70-0F2FD16AE41AQ43940878-16CB46AB-A738-4DFE-B8C4-8B2D86EE0C76Q44023232-B7321392-2974-431A-A7AC-6164588054CDQ45043687-5C27ACA0-4F46-43F5-BC1E-C2E9B414F3FAQ46203571-D4BC1ACB-0E6D-47F5-9966-715F39713F12Q46654332-40BE0A5A-DEE1-4482-A3DB-59B0546F8DC9Q47450166-93A02856-6AF5-4FFA-AAEC-42BCA94D07CEQ47550432-D3F2F93F-4843-493F-9387-1D8ECB2B76D1Q47603147-758124CA-1D60-4040-BC43-A8D863C88F18Q47609523-8E9E4A8A-0864-46D1-A559-9ABC71D1929DQ48411276-B611A469-CCD7-4A75-BCF6-D483F7485A5FQ49105354-E6050C6D-AEAA-409A-A6E4-0AE0F181F744Q49884676-A3960B7F-666F-41B0-9A2E-B48874D3ACF8Q50087561-8406C703-0F14-42F6-A2C3-6E495E88E5F7Q50229466-6DB55878-1E9F-4130-918A-E1BA8FBF8F60Q50626748-EC2711FC-499F-4843-93A7-139D35DD349DQ50944618-D7C610C0-9A76-4E84-848F-EB809B5240ADQ51015329-0D297910-4D88-4828-8C63-34E0CE801E60Q51311626-76A85CD8-6F3A-4B3C-A099-B7727636B321Q51334389-84BEBF19-60B2-424A-ACBD-E1DA13A0E371
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catherine Gebhard
@ast
Catherine Gebhard
@en
Catherine Gebhard
@es
Catherine Gebhard
@nl
Catherine Gebhard
@sl
type
label
Catherine Gebhard
@ast
Catherine Gebhard
@en
Catherine Gebhard
@es
Catherine Gebhard
@nl
Catherine Gebhard
@sl
prefLabel
Catherine Gebhard
@ast
Catherine Gebhard
@en
Catherine Gebhard
@es
Catherine Gebhard
@nl
Catherine Gebhard
@sl
P106
P21
P31
P496
0000-0001-7240-5822